TScan Therapeutics TCRX
NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST

TScan Therapeutics (TCRX) Receivables - Net (2023)

Updated

TScan Therapeutics (TCRX) recorded Receivables - Net of $31.93 million in Q2 2023.

Analysis

TScan Therapeutics (TCRX) Receivables - Net (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn
6 Novartis Ag 291.91 Bn 265.14 Bn -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn
9 Gsk 193.54 Bn 176.38 Bn -
10 TScan Therapeutics 18.87 Mn -434.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 31.93 Mn
API Access

TScan Therapeutics Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=TCRX&period=max&api_key=YOUR_API_KEY